Jul 01, 2024

Makati City, 21 May 2024 – Novartis Healthcare Philippines inaugurated its new office with a workspace that is designed to foster collaboration, innovation and sustainability. The new Novartis Philippines office is located on the fifth floor of the Ayala North Exchange Tower 1 in Ayala Avenue corner Amorsolo street in San Lorenzo, Makati City.

“Congratulations on the inauguration of Novartis Healthcare Philippines' new office. This milestone represents not only the growth of a remarkable company but also a steadfast commitment to innovation and sustainability,” said H.E. Ambassador Dr. Nicolas Brühl, Swiss Ambassador to the Philippines, who was the guest of honor in the event. 

He lauded Novartis as “a beacon of medical innovation, consistently pushing the boundaries of what is possible in healthcare” and acknowledged the company’s culture of creativity and excellence which has contributed significantly to improving the lives of countless individuals around the world.

“The Swiss Embassy is proud to support Novartis as it continues to lead the way in healthcare innovation and sustainability. May your new office be a hub of inspiration, collaboration, and transformative breakthroughs,” said Ambassador Brühl.

“Novartis is committed to fostering an environment of 'happy people, high performance', where our colleagues can unleash their full potential because they find joy in both their personal and professional life. By doing so, we empower them to go above and beyond, in fulfilling our mission to extend and improve people’s lives,” said Mr. Joel Chong, Country President, Novartis Healthcare Philippines.

Novartis Philippines inaugurates new office
Photo shows (from left) Joel Chong, Country President, Novartis Healthcare Philippines; H.E. Ambassador Dr. Nicolas Brühl, Swiss Ambassador to the Philippines; and Gaurav Dass, Chief Financial Officer, Novartis Healthcare Philippines, during the ribbon-cutting ceremony.
Novartis Philippines inaugurates new office
Novartis Philippines inaugurates new office

FA-11223813 – JUNE2024 – JUNE2026